ALTERITY THERAPEUTICS LTD (ATHE) Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Alterity Therapeutics Limited NASDAQ:ATHE Healthcare · Biotechnology
Mkt Cap $37.42M
EV -
SI 0.1%
Net Cash/Sh -
CLOSED · Nov 16 +0.00% $1.96
CLOSED · Nov 16 Prev close $1.96 0.00% Close $1.96 0.00% AH close $1.96 VOL 13K $ Vol $26K RVOL 0.06x
Mkt Cap $37.42M
EV -
VOL 13K sh
$ Vol $26K
RVOL 0.06×
SI 0.1%
Net Cash/Sh -
Press Release
Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference
globenewswire.com • 4d ago Press Release ● Major
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
globenewswire.com • 17d ago Press Release
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
globenewswire.com • 1mo ago Press Release ● Major
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders
globenewswire.com • 1mo ago Press Release
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
globenewswire.com • 2mo ago Press Release ● Major
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
globenewswire.com • 3mo ago Press Release
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
globenewswire.com • 3mo ago Press Release ● Major
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
globenewswire.com • 3mo ago Press Release
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
globenewswire.com • 3mo ago Press Release ● Major
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
globenewswire.com • 4mo ago Press Release ● Major
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
globenewswire.com • 5mo ago Press Release ● Major
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
globenewswire.com • 5mo ago Press Release
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
globenewswire.com • 6mo ago Press Release
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
globenewswire.com • 6mo ago Press Release ● Major
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
globenewswire.com • 6mo ago Press Release ● Major
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
globenewswire.com • 6mo ago Press Release ● Major
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
globenewswire.com • 6mo ago Press Release ● Major
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
globenewswire.com • 6mo ago